Stocks · News reference

RBC Raises Price Target on Novartis to CHF130

Oct 28, 2026, 2:01 PM

RBC Capital Markets has increased its price target for Novartis AG from CHF120 to CHF130 while maintaining a Sector Perform rating.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncOct 28, 2026, 5:00 PMDelveinsight
Global Dermatological Therapeutics Market to Reach USD 97 Billion by 2034 | DelveInsight
The global dermatological therapeutics market is projected to grow from USD 43 billion in 2025 to USD 97 billion by 2034, with a CAGR of approximately 10%. Growth is driven by rising prevalence of chronic skin disorders, adoption of biologics and JAK inhibitors, increased healthcare spending, and growing awareness of skin health. North America leads the market with 46% share, while Asia-Pacific is expected to register the fastest growth.
ABBV LLY JNJ NVS BMY
Fiscal.aiOct 28, 2026, 1:01 PM
Novartis Initiates Second Phase 2 Clinical Study for VAV1-Directed Molecular Glue Degrader MRT-6160
Novartis has launched a second Phase 2 clinical trial for the molecular glue degrader MRT-6160, targeting moderate to severe psoriatic arthritis.
NVS
Fiscal.aiOct 27, 2026, 3:31 PM
Novartis Discontinues Late-Stage Trial for Remibrutinib in Myasthenia Gravis
Novartis has stopped a late-stage clinical trial for its drug remibrutinib in patients with generalized myasthenia gravis due to a lack of efficacy.
NVS